TORONTO, ONTARIO, Molecular diagnostics company developing a new technology for decentralized, rapid diagnostic testing, closed a Series A financing totaling $10 million. The financing was co-led by CTI Life Sciences Fund (CTI) and the Ontario Emerging Technologies Fund (OETF) with significant participation by QIAGEN.